Vor Ort
Merkzettel Warenkorb
Produktbild: Alzheimer's Disease and Advanced Drug Delivery Strategies

Alzheimer's Disease and Advanced Drug Delivery Strategies

184,99 €

inkl. gesetzl. MwSt., Versandkostenfrei

Beschreibung

Produktdetails

Einband

Taschenbuch

Erscheinungsdatum

04.12.2023

Herausgeber

Bhupendra G. Prajapati + weitere

Verlag

Elsevier Science & Technology

Seitenzahl

490

Maße (L/B)

27,6/21,6 cm

Gewicht

1340 g

Sprache

Englisch

ISBN

978-0-443-13205-6

Beschreibung

Portrait

Dr. Bhupendra Gopalbhai Prajapati is Professor (Research Cadre) at Parul Institute of Pharmacy, Parul University, Gujarat, India, and serves as Adjunct Professor in the Department of Industrial Pharmacy at Silpakorn University, Thailand. His academic, research, and industry expertise focuses on lipid-based formulations, nano- and microparticulate drug delivery systems, and strategies to enhance drug bioavailability. Dr. Prajapati has received several academic and professional honors recognizing excellence in teaching and research. He has made substantial scholarly contributions through research and review publications, book chapters, and edited volumes in pharmaceutical sciences. Actively engaged in postgraduate and doctoral mentoring, he supports research training in advanced drug delivery and formulation science. Dr. Prajapati also serves in editorial and section-editor roles for international scientific publications, contributing to the advancement and quality of pharmaceutical research dissemination. Dr. Chellappan is affiliated with International Medical University (IMU), Kuala Lumpur, Malaysia, where he serves in the Department of Life Sciences. He has active teaching experience and focuses his research on inflammation in biological systems. Dr. Chellappan completed his doctoral training in Pharmaceutical Sciences at Manipal University, India. He has published extensively in peer-reviewed research and works as a reviewer for multiple scientific journals, alongside serving on editorial boards. His scholarship supports ongoing investigations into inflammatory pathways and their relevance to health and disease, and he contributes to academic education through coursework and mentoring within his institution. Dr. Kendre currently serving as Vice-Principal and head of the Department of Pharmaceutics at Rajarshi Shahu College of Pharmacy in Buldana, Maharashtra, India. He has more than 17 years of academic, research and industrial experience. He published more than 60 research articles. He published an Indian patent and a number of book chapters with reputable publishing houses.

Produktdetails

Einband

Taschenbuch

Erscheinungsdatum

04.12.2023

Herausgeber

Verlag

Elsevier Science & Technology

Seitenzahl

490

Maße (L/B)

27,6/21,6 cm

Gewicht

1340 g

Sprache

Englisch

ISBN

978-0-443-13205-6

Herstelleradresse

Libri GmbH
Europaallee 1
36244 Bad Hersfeld
DE

Email: gpsr@libri.de

Noch keine Bewertungen vorhanden

Verfassen Sie die erste Bewertung zu diesem Artikel

Helfen Sie anderen Kundinnen und Kunden durch Ihre Meinung.

Kundinnen und Kunden meinen

Bewertungen (0)
Die Leseprobe wird geladen.
  • Produktbild: Alzheimer's Disease and Advanced Drug Delivery Strategies
  • Contributors
    About the editors
    Preface
    Acknowledgments

    1. Etiology, pathogenesis of Alzheimer's disease and amyloid beta hypothesis
    SARIKA MARUTI KAMBLE, KALPESH RAMDAS PATIL AND AMAN B. UPAGANLAWAR

    1. Introduction
    2. Etiology of Alzheimer's disease
    3. Pathogenesis of Alzheimer's disease
    4. Diagnosis of AD
    5. Amyloid beta protein hypothesis
    6. Consequences of amyloid beta (Ab) formation
    7. Genetic factors responsible for the Alzheimer's disease
    References

    2. Neuroinflammation in Alzheimer's disease
    MOHIT AGRAWAL, MANMOHAN SINGHAL, BHUPENDRA GOPALBHAI PRAJAPATI, HEMA CHAUDHARY, YASH JASORIA, BHAVNA KUMAR, MANDEEP KUMAR ARORA AND JAGANNATH SAHOO

    1. Introduction
    2. History of neuroinflammation in AD
    3. The concept of neuroinflammation in AD
    4. Neuroinflammation: Causes and consequences of Alzheimer's disease
    5. BBB integrity and neuroinflammation
    6. Role of cellular players
    7. Role of mediators and modulators in neuroinflammation
    8. Role of intracellular signaling pathway
    9. Genetic studies
    10. Imaging of neuroinflammation in AD
    11. Possible intervention of neuroinflammation in AD
    12. Factors associated with neuroinflammation
    13. Development of therapeutic potential
    14. Conclusion
    References

    3. Recent updates in chemistry of Alzheimer's: Synthetic molecules
    DEEPAK K. LOKWANI, SANGITA R. CHAVAN, VINOD G. UGALE, PRAKASH N. KENDRE AND SHIRISH P. JAIN

    1. Introduction
    2. MTDL approach associated with following scaffold or structures
    3. Conclusion
    References

    4. Blood brain barrier and its significance in drug delivery to brain in Alzheimer disease
    DHWANI RANA, SAGAR SALAVE, DIGNESH KHUNT AND DERAJRAM BENIVAL

    1. Introduction
    2. Blood brain barrier
    3. Current treatments for AD
    4. Emerging therapies for AD
    5. Nanotherapeutics for AD
    6. Other approaches for crossing BBB
    7. Conclusion and future perspective
    References

    5. Nose to brain delivery for the treatment of Alzheimer's disease
    DIGNESH KHUNT, SAGAR SALAVE, DHWANI RANA, DERAJRAM BENIVAL, BHAVIN GAYAKVAD AND BHUPENDRA GOPALBHAI PRAJAPATI

    1. Introduction
    2. The nose-to-brain (N2B) pathway
    3. AZD and current treament
    4. Development of N2B delivery for AZD
    5. Approaches to modulation of N2B delivery in AZD
    6. Advantages of N2B delivery for AZD
    7. Conclusion and future directions
    References

    6. Amyloid cascade hypothesis, tau synthesis, and role of oxidative stress in AD
    JIGAR VYAS, NENSI RAYTTHATHA AND BHUPENDRA GOPALBHAI PRAJAPATI

    1. Introduction to the amyloid (amyloid-beta peptide)
    2. Biogenesis of amyloid-beta
    3. Amyloid cascade hypothesis (ACH)
    4. Pros and cons of the ACH
    5. Therapeutic targeting for amyloid-beta in Alzheimer's pathogenesis
    6. Tau protein
    7. Role of oxidative stress in AD
    8. Corelation of amyloid B protein, tau process, and oxidative stress in AD
    References

    7. New biologicals and biomaterials in the therapy of Alzheimer's disease
    VIPUL PRAJAPATI, SHRADDHA SHINDE, PRINCY SHRIVASTAV AND BHUPENDRA GOPALBHAI PRAJAPATI

    1. Introduction
    2. Potential target for Alzheimer's disease therapy
    3. Biologicals used in therapy of Alzheimer's disease
    4. Biomaterials used in therapy of Alzheimer's disease
    5. Nanoparticles in the therapy of Alzheimer's disease
    6. Metal nanoparticles for Alzheimer's disease treatment
    7. Other NPs
    8. Systems based on biomaterials for mass production of therapeutic cells
    9. Challenges of biomaterial-based drug delivery approach in Alzheimer's disease
    10. Conclusion
    References

    8. Roles of nano medicine in diagnosis of Alzheimer's disease
    MONA AMIT KAUSHAL, NIKITA A. PATEL, GAURAVI XAVIER AND BHUPENDRA GOPALBHAI PRAJAPATI

    1. Introduction
    2. Diagnostic tools for AD
    3. Future perspective of nano medicine and their effectiveness
    4. Conclusion and limitations
    References

    9. Nanotechnology-based delivery for CRISPR-Cas 9 cargo in Alzheimer's disease
    SHRUTI RAWAL, AKRUTI KHODAKIYA AND BHUPENDRA GOPALBHAI PRAJAPATI

    1. Introduction
    2. Genome editing by CRISPR-Cas system
    3. Genome editing targets and scope of CRISPR-Cas 9 technology in Alzheimer's disease
    4. Barriers and challenges to CRISPR-Cas 9 delivery
    5. Synergizing nano and CRISPR: Nanocarriermediated delivery
    6. Conclusions and prospects
    References

    10. Liposomes as carrier for drug delivery in Alzheimer's disease
    RAVISH J. PATEL, AMIT A. PATEL, NIDHI TRIVEDI, VIDHI PANDYA, AMIT ALEXANDER, VIRAL PATEL, BHUPENDRA GOPALBHAI PRAJAPATI AND PUNIT B. PAREJIYA

    1. Introduction
    2. Liposomes as nanocarrier system for drug delivery
    3. Liposome preparation materials and process
    4. Modification of liposomes
    5. Liposome's potential as drug delivery for AD
    6. Conclusion
    Acknowledgment
    References

    11. PLGA mediated drug delivery for Alzheimer's disease
    TOSHA PANDYA, MANGESH KULKARNI, SHEETAL ACHARYA AND BHUPENDRA GOPALBHAI PRAJAPATI

    1. Introduction
    2. PLGA in Alzheimer's disease
    3. Applications of PLGA in treatment of AD
    4. Animal models for testing AD targeted PLGA formulations
    5. Patents
    6. Conclusion and future prospective
    References

    12. Regulatory and ethical concerns in the use of nanomaterials
    NAKSHEE MEHTA, SRISHTI SHETTY, BHUPENDRA GOPALBHAI PRAJAPATI AND SARITHA SHETTY

    1. Introduction
    2. Nanomaterials
    3. Existing regulations on nanomaterials
    4. Regulatory concerns involved with the use of nanomaterials
    5. Nanomaterials in formulations and drug delivery systems to treat Alzheimer (AD)
    6. Ethical concerns involved with the use of nanomaterials
    7. Future challenges and policies
    References

    13. Symptoms and conventional treatments of Alzheimer's disease
    MEHUL R. CHORAWALA, AAYUSHI C. SHAH, AANSHI J. PANDYA, NIRJARI R. KOTHARI AND BHUPENDRA GOPALBHAI PRAJAPATI

    1. Introduction
    2. Recent neuropathological aspects
    3. Clinical presentation
    4. Conventional therapeutic approaches
    5. Hardships faced by caregivers
    6. Need of treatments although AD is incurable
    7. Recent advances in AD treatments
    8. Conclusion and outlooks
    References

    14. Dendrimers in the management of Alzheimer's disease
    CHETNA MODI, BHUPENDRA GOPALBHAI PRAJAPATI, SUDARSHAN SINGH, ADITYA SINGH AND SHUBHRAT MAHESHWARI

    1. Introduction
    2. Synthesis method of dendrimers
    3. Types of dendrimers
    4. Method of drug loading in dendrimers
    5. Properties of dendrimers
    6. Characterization of dendrimers
    7. Animal models: In vitro and in vivo studies
    8. Applications in treatment of Alzheimer's disease
    9. Clinical trials
    10. Patents
    11. Conclusion
    References

    15. Precision medicines for the treatment of Alzheimer's disease
    SANGAMESHWAR B. KANTHALE, PRAKASH N. KENDRE, SOMNATH K. VIBHUTE, SHIRISH P. JAIN AND SHRADHA S. TIWARI

    1. Introduction
    2. Background
    3. Comprehensive risk determination
    4. Intervention design
    5. Methodology
    6. System biology method for AD research
    7. Role of genetics in precision medicine
    8. Nanoparticles as precision medicines in AD
    9. Discovery, development, and validation of pathophysiological biomarker candidates in AD
    10. Challenges in AD risk reduction
    11. Next step and future directions
    12. Conclusion
    References

    16. Nanoformulations targeting Alzheimer's disease
    DEVESH KAPOOR, DEEPAK SHARMA, YASHWANT PATHAK, BHUPENDRA GOPALBHAI PRAJAPATI AND BHAVIK SATANI

    1. Introduction
    2. Overview of BBB and B-CSFB
    3. Obstacles in drug delivery to BBB/B-CSF in ADs
    4. Nanocarrier based nanoformulations to combat AD's
    5. Carbon dots (CDs)
    6. Nanodiamonds (NDs)
    7. Fullerene
    8. Nanotubes
    9. Conclusion
    References

    17. Lipid nanoparticles in targeting Alzheimer's disease
    PRAKASH N. KENDRE, AJINKYA POTE, RASIKA BHALKE, BHUPENDRA GOPALBHAI PRAJAPATI, SHIRISH P. JAIN AND DEVESH KAPOOR

    1. Introduction
    2. Different types of LNs used in AD
    3. Lipids nanoparticles (LNs) and AD
    4. Limitations of LNs in CNS diseases
    5. Regulatory considerations of LNs
    6. Future prospective and conclusion
    References

    18. Novel therapeutic approaches for targeting Alzheimer's disease
    AKRUTI KHODAKIYA, SUNITA CHAUDHARY, ANKIT CHAUDHARY AND BHUPENDRA GOPALBHAI PRAJAPATI

    1. Alzheimer's disease: Scope of new therapeutic approaches
    2. FDA approved drugs for Alzheimer's disease
    3. Novel therapeutic approaches
    4. Conclusion and future perspectives
    References

    19. Micro and nanoemulsion as drug carriers in Alzheimer's disease
    AMI PATEL, HIMANSHU PALIWAL, KRUTIKA SAWANT AND BHUPENDRA GOPALBHAI PRAJAPATI

    1. Introduction
    2. Microemulsion and nanoemulsion formulation
    3. Physicochemical characterization of formulations
    4. Applications, current research and patent landscape of microemulsions and nanoemulsion
    5. Pharmacokinetics and pharmacodynamic of developed NE/ME for AD
    6. Conclusion and future perspectives
    References

    20. Targeted nanotechnology-based formulations
    ANGELA CHINASA ANI, STEPHEN CHIJIOKE EMENCHETA, KOSARACHI JENNIFER ORAH, AMAN B. UPAGANLAWAR, BHUPENDRA GOPALBHAI PRAJAPATI, CHUKWUKA KANAYO ORANU AND CHUKWUEMEZUE PRAISES ONYEKWE

    1. Introduction
    2. Nanomaterials
    3. Targeted nanotechnology-based formulations (TNbF)
    4. Applications of targeted nanoformulations
    5. Concerns in the design and application of nanoformulations
    6. Clinical data
    7. Prospects in the design of targeted nanoformulation
    8. Conclusion
    References

    21. Drug delivery for Alzheimer's disease using nanotechnology: Challenges and advancements
    BINDIYA CHAUHAN, SHIVANI PATEL, BHUPENDRA GOPALBHAI PRAJAPATI AND SUDARSHAN SINGH

    1. Introduction
    2. Drug delivery strategies for Alzheimer diseases
    3. Alzheimer's disease clinical requirement and drug delivery challenges
    4. Nanomedicine as future aspect in treatment of Alzheimer diseases
    5. Nonmicellar based formulation
    6. Dendrimers
    7. Nanogels
    8. Alzheimer diseases treatment with lipid-based nanoparticles
    9. Metallic nanoparticles
    10. Nanoparticulate-chelation-based Alzheimer diseases therapy
    11. Nanomedicine theranostics formulations
    12. Protein-coated nanoparticles
    13. Antibody decorated nanoparticles
    14. Novel biomarkers used in diagnosis of Alzheimer diseases
    15. Conclusion and future perspective
    References

    22. Current trends and updates in the treatment of Alzheimer's disease
    NISHA H. PARIKH, PALAK K. PARIKH, HETANSH J. RAO, KASHISH SHAH, BHAVARTH P. DAVE AND BHUPENDRA GOPALBHAI PRAJAPATI

    1. Introduction
    2. Pathophysiology and multifactorial nature of AD
    3. Current treatment approaches for AD
    4. Potential therapeutic strategies for AD
    5. Conclusion and perspective
    References

    23. Pharmacokinetics and pharmacodynamics of various novel formulations targeting Alzheimer's disease
    ASHWINI GAWADE, SATISH POLSHETTIWAR, HETAL HINGALAJIA, BHUPENDRA GOPALBHAI PRAJAPATI AND ADITYA SINGH

    1. Introduction
    2. Alzheimer's disease
    3. Currently available drug molecules for the management for AD
    4. Treatments for AD in the CNS: Clinical pharmacokinetics and pharmacodynamics
    5. Nanoparticle delivery system for the management of AD and their PK PD
    6. Conclusion
    References

    24. Microbubbles-based drug delivery for antiAlzheimer's drugs
    MEENAKSHI PATEL, BHUPENDRA GOPALBHAI PRAJAPATI AND M.R. YADAV

    1. Introduction
    2. Ultrasound mediated microbubble therapy to overcome BBB for treating Alzheimer's patients
    3. Drug loaded lipid based microbubbles for AD
    4. In vitro cell models of BBB for AD and microbubble-mediated drug delivery
    5. Clinical trials of microbubble-based drug delivery for treatment of AD
    6. Challenges and toxicity concerns of microbubble-based drug delivery for AD
    7. Future aspects and conclusion
    References

    25. Neurotoxicity with the use of nanomaterials
    SACHIN P. BORIKAR, SHIRISH P. JAIN, DEEPALI N. TAPRE, DEBARSHI KAR MAHAPATRA, ASAVARI V. MAHAJAN, DIPAK S. SONAWANE AND PRAKASH N. KENDRE

    1. Introduction
    2. Toxicity associated with nanomaterials
    3. Brain as nanoparticles target
    4. Properties of nanoparticles that influence toxicities
    5. Mechanisms of neurotoxicity
    6. Mitochondrial dysfunction due to nanoparticles
    7. DNA damage due to nanoparticles
    8. Endocrine dysfunction due to nanoparticles
    9. Conclusion
    References

    26. Combinatorial therapy in Alzheimer's disease
    MAHENDRA GIRI, PRAKASH N. KENDRE, RASIKA BHALKE, VISHAL PANDE, KALYANI AUTADE AND RAJASHRI SUMBE

    1. Introduction
    2. Diagnostic criteria for Alzheimer's disease
    3. Combinatorial treatment strategies for Alzheimer's disease
    4. On-going clinical trialon AD
    5. Summary
    References

    Index